Hetero is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $21.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Hetero's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Jul 2025 | $7.7B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Sep 2024; launched Mar 2026 | $2.7B |
| Descovy | Gilead | Generic | 2031 | Settled 2022 | $2.8B |
| Rinvoq | AbbVie | Generic | 2037 | Settled Sep 2025 | $8.3B |
Company facts: Hetero. Each drug page lists sources for these entries. Brand sales show the size of the market, not Hetero's share of it.